# A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

> **NCT00764946** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 209 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **DRUG:** Comparator: raltegravir

## Key facts

- **NCT ID:** NCT00764946
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00764946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00764946, "A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00764946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*